Genmab — Maj 2021
-
Mandagens aviser med ISS, TDC og Novo Nordisk https://www.proinvestor.com/investornyt/675091/mandagens-aviser-med-iss-tdc-og-novo-nordisk
-
Vi mangler stadig flere spørgsmål til Q&A.
-
-
God morgen .
-
Genmab har fået et nyt kursmål, efter at JPMorgan har løftet sit kursmål til 2500 kr. fra 2350 kr. Genmab-aktien steg onsdag 0,1 pct. til 2231 kr.: https://www.proinvestor.com/investornyt/675102/aktier-tendens-maersk-og-ambu-indtager-hovedroller-i-positivt-marked
-
God formiddag
-
Flot Stockbull.
-
Aktier/åbning: Ambu, Genmab og Ørsted til tops i grøn åbning https://www.proinvestor.com/investornyt/675107/aktier-abning-ambu-genmab-og-orsted-til-tops-i-gron-abning
-
17.5.2021 10.34 · GlobeNewswire
Transactions in connection with share buy-back program
Company AnnouncementCOPENHAGEN, Denmark; May17, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program.
The share buy-back program is expected to be completed no later than June 30, 2021 and comprises up to 200,000 shares....
-
The following transactions were executed under the program from May 10, 2021 to May 14, 2021:
No. of shares Average price (DKK) Total value (DKK)
Accumulated through last announcement 136,800 286,652,775
May 10, 2021 1,400 2,286.59 3,201,226
May 11, 2021 1,400 2,228.91 3,120,474
May 12, 2021 May 13, 2021 1,500 0 2,243.32 N/A 3,364,980 0
May 14, 2021 0 N/A 0
Total 4,300 9,686,680
Accumulated under the program 141,100 296,339,455
-
Sorry Stroka at jeg blandede mig. Jeg troede at du havde glemt noget af meddelelsen.
-
@stockbull - tillykke med salget i morges. Pas nu på du ikke presser prisen for meget, når du genkøber til eftermiddag
-
** Genmab GMAB.CO shares are up 3.5% after J.P. Morgan raises its share price target for the Danish biopharmaceutical company to 2,500 Danish crowns from 2,350 crowns
** The brokerage sees several important updates from the company in the second half of the year, particularly on its GEN1046 and epcoritamab treatments
** It moves forward its expected launches for both treatments to 2024, from 2025 previously, based on comments during the company's Q1 results call -
** JPM forecasts 2021 revenues of 7.50 billion crowns ($1.23 billion) and operating income of 1.86 billion crowns, both towards the upper end of the company's guidance range
** It reiterates an "overweight" rating on the stock
** Out of 27 analysts that cover Genmab, 18 rate the stock "strong buy" or "buy", six rate it "hold" and three rate it "strong sell" or "sell" -
Nordea's kommenterer ligeledes i dag. Ser signifikant nyhedsflow fra pipeline de naeste 6 maaneder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind